MA-VERISTAT
7.4.2021 14:02:07 CEST | Business Wire | Press release
Veristat , a scientific-minded, global clinical research organization (CRO), announced today that it transferred its majority ownership from Variance Development Partners to WindRose Health Investors (WindRose). WindRose invests exclusively in healthcare companies and has extensive experience across the healthcare services landscape, including outsourced biopharmaceutical services like Veristat’s.
“As a founder of Veristat, I believe that Veristat has attained the ideal investment partner who understands our philosophy, our values, and the impact we make in clinical research,” stated John P. Balser, Ph.D., President, Co-Founder, and Chief Statistical Officer of Veristat. “WindRose has a track record of successful collaboration, understands the critical nature of the scientific and therapeutic expertise we offer and will bring significant knowledge and a network of advisors to assist us as we continue to evolve.”
WindRose will support Veristat’s continued expansion to meet the needs of its growing client base around the world. This partnership will significantly benefit Veristat by complementing the leadership team with a group of diverse and knowledgeable healthcare advisors who share the same vision, culture, and focus on scientific excellence in clinical research.
“We are excited to enter into this relationship with Veristat,” said CJ Burnes, Partner with WindRose. “The Company’s clinical impact and scientific approach to partnering with companies advancing life-enhancing therapies is impressive. Their market position, stellar reputation, and leadership within biostatistics and ability to design and conduct complex clinical trials is unlike any other we have seen. In partnership with the management team and the founders, WindRose plans to contribute substantial resources to support the execution of Veristat’s strategy.”
“I am confident that our partnership with WindRose will allow Veristat’s continued focus on our core mission of helping sponsors solve the challenges that arise when developing ground-breaking products that improve and save lives through our differentiated approach to designing and executing clinical trials, clinical programs, regulatory submissions, and pharmacovigilance,” stated Patrick Flanagan, Chief Executive Officer of Veristat. “WindRose will provide us the capital and a deep network of relationships and expertise in the biotech and pharmaceutical industry as we strategically grow our company.”
Edgemont Partners acted as financial advisor to Veristat. Nutter McClennen & Fish LLP acted as legal advisor to Veristat, and McDermott Will & Emery LLP acted as legal advisor to WindRose.
About WindRose
WindRose makes equity investments in companies that operate within the services sectors of the healthcare industry. The firm focuses on companies with profitable business models and a demonstrated ability to deliver cost-effective solutions. WindRose manages over $1.2 billion in investments and is currently investing out of its fifth fund. WindRose is based in New York City and invests in companies throughout the United States.
For more information, email WindRose at info@windrose.com .
About Veristat
Veristat , a global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared over 100 marketing applications for approval with global regulatory authorities in the last 10 years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005346/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Robbyant Upgrades and Open-Sources LingBot-VLA 2.0 as a Next-Generation Universal Brain for Embodied AI8.7.2026 10:11:00 CEST | Press release
Robbyant, an embodied AI company within Ant Group, today announced the upgrade and open-source release of LingBot-VLA 2.0. Building upon the foundation of LingBot-VLA 1.0 released in January 2026, this next-generation vision-language-action (VLA) model delivers significant leaps in morphological generalization, degrees of freedom (DoF) support, and deployment efficiency, delivering a more advanced “universal brain” for scalable real-world robotics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707394646/en/ LingBot-VLA 2.0 supports a wide range of robot morphologies While the embodied AI industry is witnessing rapid advancements in hardware and control systems, the lack of a truly universal brain remains a primary bottleneck for industrial-scale deployment. LingBot-VLA 2.0 addresses this critical gap by dramatically expanding its pre-training data and architectural capabilities. LingBot-VLA 2.0 was pre-trained on 60,000
TetraMem and SK hynix Showcase Successful Technology Collaboration Advancing Memory-Centric AI Computing8.7.2026 10:06:00 CEST | Press release
Joint achievement highlights how Analog In-Memory Computing can address the growing energy and thermal challenges of AI while laying the foundation for deeper collaboration on next-generation memory and computing architectures. TetraMem Inc., a leader in Analog In-Memory Computing (A-IMC) technology, and SK hynix Inc., a global leader in AI memory and semiconductor technologies, today announced the successful completion of a joint technology collaboration, highlighted by the publication of their research paper, “A Memristor-based In-Memory Computing SoC with Efficient Depthwise Convolution,” in Advanced Intelligent Systems. The work has also been selected as the cover feature of the journal, recognizing its technical innovation and potential impact on next-generation AI computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708244132/en/ The collaboration brings together SK hynix’s expertise in advanced memory technolo
Vultr and SUSE Launch Validated Full-Stack NVIDIA Enterprise AI Platform to Accelerate Production Deployments8.7.2026 10:00:00 CEST | Press release
SUSE AI Factory with NVIDIA on Vultr Infrastructure delivers integrated enterprise AI software, GPU acceleration, and global cloud infrastructure to move organizations from AI experimentation to secure production Vultr, the world's largest privately-held cloud infrastructure company, today announced the launch of SUSE AI Factory with NVIDIA on Vultr infrastructure, developed in partnership with SUSE. Announced alongside SUSE at the RAISE Summit in Paris, this validated, full-stack enterprise AI platform combines enterprise-grade AI software, advanced GPU acceleration, and global AI infrastructure into a single, production-ready solution. As organizations look to move AI workloads from experimentation into production, this joint solution eliminates the complexity of building AI stacks from scratch, allowing enterprises to deploy secure, scalable AI applications with ease. The solution combines software and infrastructure capabilities to help organizations securely and reliably advance a
NetApp Named Presenting Partner of 2026 NFL Madrid Game8.7.2026 10:00:00 CEST | Press release
League’s Official Intelligent Data Infrastructure Partner Extends Its Presence Across the NFL’s International Games The NFL today announced that the league’s Global Partner, NetApp (NASDAQ: NTAP), the Intelligent Data Infrastructure company, will return as Presenting Partner of the 2026 NFL Madrid Game, featuring the Atlanta Falcons taking on the Cincinnati Bengals at the Bernabéu Stadium — home to Real Madrid C.F. — on Sunday, Nov. 8. The multi-year announcement builds on NetApp’s role as the league’s Official Intelligent Data Infrastructure Partner and Presenting Partner of the inaugural NFL Madrid Game in 2025 and continues the company’s support of the league’s international games. “We are delighted to welcome NetApp back as Presenting Partner of the NFL Madrid Game,” said Rafa De Los Santos, country manager of NFL Spain. “Last year’s game at the Bernabéu was a landmark moment for the NFL in Spain, and with the Falcons and Bengals bringing two of the most exciting teams in football
MSIG Europe Selects Clearwater Analytics to Modernize Investment Operations8.7.2026 10:00:00 CEST | Press release
Selection extends MS&AD Group’s global relationship with Clearwater, bringing a unified platform for investment data, accounting, regulatory reporting, and analytics to MSIG Europe Clearwater Analytics today announced that MSIG Europe, a wholly owned subsidiary of MS&AD Insurance Group, has selected the Clearwater platform to modernize its operating model, unify data across the investment lifecycle, and meet the demands of the European regulatory environment, including Belgian GAAP, IFRS and Solvency II. European insurers are navigating the convergence of tightening regulatory demands, growing allocations to private markets, and the operational limits of fragmented legacy systems. The firms moving fastest are consolidating onto platforms that deliver daily accuracy, compliance automation, and integrated analytics at scale. MSIG is a wholly-owned subsidiary of Mitsui Sumitomo Insurance and a member of the MS&AD Insurance Group, one of Asia’s leading non-life insurance brands with a pres
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom